Boundless Bio (BOLD)

• Market cap: $57.8M
• 1 day: 2.78%
• 5 days: 3.60%
• 1 month: -4.43%
• 3 months: -41.14%
• 6 months: -52.91%
• Year to date: -81.82%
• 1 year: -81.82%
• 5 years: -81.82%
• 10 years: -81.82%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 72

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

15% more funds holding

Funds holding: 47 [Q2] → 54 (+7) [Q3]

4.09% less ownership

Funds ownership: 63.02% [Q2] → 58.93% (-4.09%) [Q3]

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

70% less capital invested

Capital invested by funds: $151M [Q2] → $45.5M (-$105M) [Q3]